EPZM News and Press, Epizyme Inc. From 08/18/19

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 117 weeks of public selections as part of this ongoing live forward-testing. ...

Epizyme ( EPZM ) announced that the FDA had accepted its NDA for tazemetostat for patients with metastatic or locally advanced epithelioid sarcoma not eligible for surgery. This sets up the biotech to potentially obtain approval at the beginning of 2020. Best part of all is that this dru...

Epizyme (NASDAQ: EPZM ): Q2 GAAP EPS of -$0.53 misses by $0.01 . More news on: Epizyme, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Tazemetostat NDA Submission Accepted for Priority Review for Epithelioid Sarcoma Industry Veteran Paolo Tombesi Appointed as Chief Financial Officer Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today provided business ...

Epizyme, Inc . (Nasdaq:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will present at the Wedbush PacGrow 2019 Healthcare Conference on Tuesday, Aug. 13, 2019 at 10:55 a.m. ET i...

Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year test of the top three forensic algorithms used to detect bankruptcy risk, earnings manipulation, and financial irregularities. My forward testing compiles portfolio ...

Epizyme ( EPZM -3.3% ) slips on modestly higher volume after announcing that the FDA has accepted for review its marketing application seeking accelerated approval for tazemetostat for the treatment of epithelioid sarcoma. As is typical for a filing like this, the bulk of the supporting ...

The FDA accepts for review Epizyme's (NASDAQ: EPZM ) marketing application seeking approval to use tazemetostat to treat metastatic or locally advanced epitheloid sarcoma not eligible for curative surgery. The agency's action date is January 23, 2020. More news on: Epizyme, Inc., Healthc...

Company Aligns with FDA on Planned Confirmatory Study Design for Tazemetostat in Epithelioid Sarcoma Company to Host Conference Call Today, July 25, 2019, at 8:30 a.m. EDT Epizyme, Inc . (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies...

Epizyme, Inc . (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced the appointment of Paolo Tombesi as chief financial officer, effective August 2019. Mr. Tombesi brings over 30 years of extensive financial and accounting expertise to...